UK Seeks Resolution with Big Pharma – Pharmaceuticals Industry

Here’s ⁢a summary of the key points from ⁤the provided text:

*⁣ Pharmaceutical Companies are Pulling Back: ⁤Major pharmaceutical companies, Merck (MSD in Europe) and AstraZeneca, are scaling back⁤ investments in UK research and progress. ⁢Merck⁣ cancelled a £1bn‍ London ⁣research center and laid off 125 ‍scientists, while AstraZeneca⁢ paused a £200m laboratory project in Cambridge and previously abandoned a £450m vaccine site investment.
* Reasons⁣ Cited: Thes companies‍ cite⁣ a lack of investment in the UK life science industry and cuts in government support as key reasons for their decisions. Specifically, Merck blamed “the challenges ⁢of the UK not making meaningful progress towards addressing the lack of investment.”
* NHS ⁣Spending on Medicines: Sir Patrick Vallance, the former chief scientific advisor, pointed out that NHS spending on medicines has been⁤ declining as a percentage of total healthcare spending as 2015, though he stated it is indeed expected to increase to 9%.
* Need for Change: Ther’s a recognition that the UK needs to change its approach to drug pricing and access. Officials are discussing linking the drugs regulator (MHRA) and the National⁢ Institute for Health and Care Excellence (NICE) and considering new pricing models that ‍account for the economic and⁤ clinical benefits of cutting-edge (and often expensive) treatments.
* Ongoing Discussions: While formal‍ talks with the pharmaceutical industry over the medicine pricing ⁢mechanism (which recently collapsed) haven’t restarted, ministers are engaged in “lots of discussions around the commercial surroundings in the UK” with companies.

In essence, the⁤ article highlights a growing concern that the ⁤UK is becoming ⁤a less attractive location for pharmaceutical investment due to pricing pressures⁣ and a perceived lack of support for the life sciences industry.